Sanderink GJ, Guimart CG, Ozoux M-L, Jariwala NU, Shukla UA, Boutouyrie BX. Pharmacokinetics and phar- macodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res. 2002;105(3):225-231. 157. Schmid P, Brodmann D, Odermatt Y, Fischer AG, Wuillemin WA. Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insuf ciency. J Thromb Haemost. 2009;7(10):1629-1632. 158. Mismetti P, Laporte-Simitsidis S, Navarro C, et al. Aging and venous thromboembolism in uence the pharmacody- namics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost. 1998;79(6):1162-1165. 159. Siguret V, Pautas E, F vrier M, et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost. 2000;84(5):800-804. 160. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta- analysis: low-molecular-weight heparin and bleeding in patients with severe renal insuf ciency. Ann Intern Med. 2006;144(9):673-684. 161. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM; ESSENCE and TIMI 11B Investigators. Safety and ef cacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J. 2003;146(1):33-41. 162. Cestac P, Bagheri H, Lapeyre-Mestre M, et al. Utilisation and safety of low molecular weight heparins: prospec- tive observational study in medical inpatients. Drug Saf. 2003;26(3):197-207. 163. Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF. Enoxaparin and bleeding complications: a review in patients with and without renal insuf ciency. Pharmacotherapy. 2000;20(7):771-775. 164. Sanderink GJ, Le Liboux A, Jariwala N, et al. The pharma- cokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72(3):308-318. 165. Rabbat CG, Cook DJ, Crowther MA, et al. 